

# David W Holt

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/10453396/david-w-holt-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106  
papers

3,859  
citations

27  
h-index

62  
g-index

107  
ext. papers

4,164  
ext. citations

3.5  
avg, IF

4.73  
L-index

#	Paper	IF	Citations
106	Amiodarone pharmacokinetics. <i>American Heart Journal</i> , <b>1983</b> , 106, 840-7	4.9	383
105	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 139-52	3.2	347
104	Therapeutic drug monitoring of mycophenolate mofetil in transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 145-54	3.2	275
103	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. <i>Transplantation</i> , <b>2002</b> , 74, 1486-9	1.8	251
102	Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 341-58	6.9	226
101	Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 305-15	3.2	221
100	The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 914-9	8.7	211
99	Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. <i>Transplantation</i> , <b>2008</b> , 86, 1043-51	1.8	209
98	Case series of individuals with analytically confirmed acute mephedrone toxicity. <i>Clinical Toxicology</i> , <b>2010</b> , 48, 924-7	2.9	174
97	Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. <i>Journal of Medical Toxicology</i> , <b>2010</b> , 6, 327-30	2.6	161
96	Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. <i>Transplantation</i> , <b>2005</b> , 79, 499-502	1.8	156
95	Substandard drugs: a potential crisis for public health. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 218-43	3.8	115
94	Therapeutic monitoring of mycophenolic acid. A consensus panel report. <i>Clinical Biochemistry</i> , <b>1998</b> , 31, 317-22	3.5	110
93	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. <i>Clinical Therapeutics</i> , <b>1999</b> , 21, 1632-52; discussion 1631	3.5	89
92	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
91	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 59-67	3.2	70
90	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 176-89	3.2	65

89	Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). <i>Journal of Medical Toxicology</i> , <b>2008</b> , 4, 254-7	2.6	51
88	Monitoring mycophenolic acid. <i>Annals of Clinical Biochemistry</i> , <b>2002</b> , 39, 173-83	2.2	49
87	The need for standardization of tacrolimus assays. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1739-47	5.5	48
86	Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. <i>Transplantation</i> , <b>2006</b> , 82, 705-8	1.8	46
85	Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. <i>Transplantation</i> , <b>2006</b> , 82, 1413-8	1.8	43
84	Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2002</b> , 11, 657-63	3.5	42
83	A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. <i>Transplantation</i> , <b>2008</b> , 85, 163-5	1.8	40
82	Standardization of LC-MS for therapeutic drug monitoring of tacrolimus. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 1630-7	5.5	35
81	Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CK-MB, and troponin-T concentrations. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1998</b> , 21, 1410-6	1.6	31
80	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. <i>Clinical Transplantation</i> , <b>2007</b> , 21, 252-7	3.8	28
79	Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). <i>Journal of Medical Toxicology</i> , <b>2008</b> , 4, 167-9	2.6	27
78	The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. <i>Molecular Diagnosis and Therapy</i> , <b>2003</b> , 3, 291-301		26
77	Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. <i>European Journal of Heart Failure</i> , <b>2001</b> , 3, 155-63	12.3	23
76	Pharmacogenomics of immunosuppressive drug metabolism. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2003</b> , 12, 607-13	3.5	22
75	First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. <i>European Journal of Emergency Medicine</i> , <b>2008</b> , 15, 354-6	2.3	21
74	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 2045-58	4	21
73	How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. <i>Transplant Immunology</i> , <b>2002</b> , 9, 211-4	1.7	21
72	Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. <i>Pharmacogenomics</i> , <b>2008</b> , 9, 585-96	2.6	19

71	Detection of the pharmaceutical agent glaucine as a recreational drug. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 553-4	2.8	19
70	Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 628-34	4.3	18
69	Genotyping cytochrome P450 3A5 using the Light Cycler. <i>Annals of Clinical Biochemistry</i> , <b>2005</b> , 42, 376-81.2	1.2	17
68	Class III antiarrhythmics in overdose. Presenting features and management principles. <i>Drug Safety</i> , <b>1993</b> , 9, 450-62	5.1	15
67	CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the Abbott immunoassay. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 2214-5	5.5	10
66	Cyclosporin monitoring based on C2 sampling. <i>Transplantation</i> , <b>2002</b> , 73, 840-1	1.8	9
65	A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. <i>Lancet, The</i> , <b>2018</b> , 391, 2411.40	1.0	8
64	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 2593-605	4	6
63	Monitoring immunosuppressive drugs: has it a future?. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 244-7	3.2	6
62	An herbal remedy for impotence: more than was bargained for. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 1379-81	2.9	4
61	Delivering quality for the measurement of immunosuppressive drugs: current performance and future needs. <i>Accreditation and Quality Assurance</i> , <b>1999</b> , 4, 427-430	0.7	4
60	Management of cardiac drug overdose. <i>Resuscitation</i> , <b>1984</b> , 11, 207-16	4	3
59	Chronic allograft damage index as a surrogate marker for chronic allograft rejection <b>2002</b> , 433-441		2
58	Effects of amiodarone on the kinetics of antipyrine. <i>American Journal of Cardiology</i> , <b>1989</b> , 63, 991-2	3	2
57	Comparison of three infant venous reservoirs with vacuum-assisted venous drainage during varying levels of cardiomy suction. <i>Perfusion (United Kingdom)</i> , <b>2020</b> , 35, 26-31	1.9	2
56	Monitoring immunosuppressive drugs. <i>Handbook of Analytical Separations</i> , <b>2004</b> , 273-296	0.7	1
55	Genomics and biomarkers in toxicology <b>2002</b> , 291-298		1
54	Evidence-based medicine: evaluation of biomarkers <b>2002</b> , 3-15		1

53	Statistical approaches to rational biomarker selection <b>2002</b> , 24-31		1
52	Biomarkers of hepatic disease <b>2002</b> , 167-176		1
51	Toxicogenetic markers of liver dysfunction <b>2002</b> , 190-198		1
50	Early markers of nephrotoxicity for environmental and occupational monitoring <b>2002</b> , 66-75		1
49	Traumatic brain injury: assessment by biochemical serum markers <b>2002</b> , 398-405		0
48	Discussion: can upper extremity (deltoid) near infrared spectroscopy be used to assess cerebral tissue bed saturation on femorally cannulated veno-arterial extracorporeal membrane oxygenation patients?. <i>Perfusion (United Kingdom)</i> , <b>2021</b> , 36, 190-199	1.9	0
47	Bone turnover markers in clinical practice <b>2002</b> , 99-114		
46	The immunogenetics of metabolic liver disease <b>2002</b> , 177-189		
45	Biomarkers in gastrointestinal disease <b>2002</b> , 265-271		
44	The use of biomarkers for monitoring the response to immunosuppressive drug therapy <b>2002</b> , 451-460		
43	Markers of malabsorption: coeliac disease <b>2002</b> , 281-288		
42	Determinants of responses to viruses and self in liver disease <b>2002</b> , 244-255		
41	Sources of preanalytical variability in the measurement of biochemical markers of bone turnover <b>2002</b> , 140-158		
40	Prognosis and management of patients with acute liver failure <b>2002</b> , 199-210		
39	Biochemical markers of bone resorption <b>2002</b> , 122-132		
38	Biomarkers in artificial and bioartificial liver support <b>2002</b> , 211-220		
37	Tumour markers in gastrointestinal disease <b>2002</b> , 272-280		
36	The impact of biochemical tests on patient management <b>2002</b> , 325-333		

- 35 Monitoring liver transplant recipients **2002**, 423-432
- 34 The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers **2002**, 76-96
- 33 Genetic approaches to the study of complex diseases: osteoporosis **2002**, 159-164
- 32 IL-6-type cytokines and signalling in inflammation **2002**, 256-262
- 31 Serum markers of inflammation and cardiovascular risk **2002**, 345-354
- 30 An overview of S-100 $\beta$  as a clinically useful biomarker of brain tissue damage **2002**, 406-412
- 29 Molecular diagnosis of cytomegalovirus disease **2002**, 467-473
- 28 Development of biomarkers: the industrial perspective **2002**, 16-23
- 27 Biomarkers in renal disease **2002**, 45-55
- 26 Biomarkers for evaluating the safety of genetically modified foods **2002**, 313-322
- 25 Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure **2002**, 334-344
- 24 Diagnosis and monitoring of inflammatory events in transplant recipients **2002**, 474-482
- 23 The clinical significance of markers of coagulation in acute coronary syndromes **2002**, 355-364
- 22 The clinical application of biomarkers in osteoporosis **2002**, 133-139
- 21 Endothelin: what does it tell us about myocardial and endothelial dysfunction? **2002**, 365-373
- 20 Biomarkers of neurodegenerative disorders **2002**, 391-397
- 19 Biomarkers of bone formation **2002**, 115-121
- 18 Homocysteine: a reversible risk factor for coronary heart disease **2002**, 374-378

- 17 Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy **2002**, 442-450
- 16 The genetics of renal disease **2002**, 56-65
- 15 Prognostic markers in liver disease **2002**, 221-227
- 14 Apoptosis: biomarkers and the key role of mitochondria **2002**, 228-238
- 13 Monitoring heart and lung transplant patients **2002**, 415-422
- 12 Post-transplantation bone disease **2002**, 461-466
- 11 Using intelligent systems in clinical decision support **2002**, 32-42
- 10 Liver regeneration: mechanisms and markers **2002**, 239-243
- 9 Protein profiling and proteomic databases **2002**, 299-312
- 8 Matrix metalloproteinases and their tissue inhibitors **2002**, 379-388
- 7 Proficiency testing schemes for therapeutics and toxicology. *Accreditation and Quality Assurance*, **2000**, 5, 389-391 0.7
- 6 Colloid Oncotic Pressure, Monitoring its Effects in Cardiac Surgery. *Journal of Extra-Corporeal Technology*, **2017**, 49, 249-256 0.4
- 5 Improving Decreased Heater-Cooler Efficiency as a Result of Heater-Cooler Infection Control Strategy. *Journal of Extra-Corporeal Technology*, **2019**, 51, 73-77 0.4
- 4 Perfusion Recruitment Strategies Using Choice-Based Conjoint Analysis. *Journal of Extra-Corporeal Technology*, **2020**, 52, 218-226 0.4
- 3 Practical Applications of Therapeutic Drug Monitoring: The impact of technological developments **1989**, 93-102
- 2 Quantification of mycophenolic acid in human plasma by liquid chromatography with time-of-flight mass spectrometry for therapeutic drug monitoring. *Biomedical Chromatography*, **2021**, 35, e5011 1.7
- 1 Alternative Input for Perfusion Management Devices: Voice Recognition for Data Input and the Effects on Charting and Perioperative Calculation Use.. *Journal of Extra-Corporeal Technology*, **2021**, 53, 286-292 0.4